February 26, 2021
FDA approves Oncopeptides’ PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
Media
February 26, 2021
Year-end report 2020
February 25, 2021
Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021
February 23, 2021
Nordic Nanovector ASA – Key information regarding potential repair offering
February 23, 2021
Nordic Nanovector – Private placement successfully completed
February 23, 2021
Nordic Nanovector launches a private placement of new shares
February 23, 2021
Continued survival benefit in Targovax’s ONCOS-102 trial in mesothelioma at the 21-month follow-up
February 18, 2021
Oncopeptides Year-end Report 2020
February 18, 2021
Targovax ASA: Annual Report 2020
February 18, 2021
Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma